These MMR-deficient tumors are more susceptible to immunotherapies like the checkpoint inhibitors, which have shown great promise in treatment for advanced CRC with MSI, demonstrating a response rate of 33-55% and durable complete remissions (18–21). This evidence concerns the gene MRC1 and colorectal carcinoma.